Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

NCT01508923 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide on blood sugar levels and digestion speed in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 17 people

Who can join Ages 18+ · all sexes

Timeline Started 2001-05 · est. completion 2002-02

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01508923 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.

Treatments tested

liraglutide also known as NNC 90-1170 Drug

6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
placebo Drug

6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

Main thing measured	24-hour glucose profiles after three fixed meals
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01508923 ↗